Clinical Consultations™: Closing the Gap in Early Identification and Treatment of SMA

Released On
July 31, 2020

Expires On
July 31, 2021

Media Type

Completion Time
75 minutes

Neurology, Pediatrics, Pharmacy, Primary Care

Pediatrics, Neonatal

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.

Supported by an educational grant from AveXis Inc. and Biogen.

Credit Available

  • Physicians — maximum of 1.25 AMA PRA Category 1 Credit(s)
  • Nurses — 1.25 Contact Hours

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is intended for OB/GYNs and neurologists, as well as physicianassistants, nurse practitioners, and nurses involved in the diagnosis and management of SMA.

Program Overview

This online educational activity is designed to provide expert interpretation of current and emerging data on the diagnosis and treatment of spinal muscular atrophy (SMA). The importance of early diagnosis and treatment, availability of carrier testing and newborn screening in some states, and current and emerging therapies will be presented in a series of videos featuring expert thought leaders in SMA.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Describe new and emerging methods of prenatal and newborn screening for SMA
  • Discuss clinical trial evidence of the benefits of early treatment initiation in patients with SMA
  • Evaluate the mechanism of action, efficacy, and safety of new and emerging agents for the treatment of SMA


Nancy L. Kuntz, MD

Attending Physician, Division of Neurology
Medical Director, Mazza Foundation Neuromuscular Program
Director, Muscular Dystrophy Association Care Center
Ann & Robert H Lurie Children’s Hospital of Chicago
Professor of Pediatrics and Neurology
Northwestern University Feinberg School of Medicine
Chicago, IL

Thomas W. Prior, PhD

Professor, Department of Pathology
Director, Molecular Genetics Laboratory
University Hospitals Center for Human Genetics
Case Western Reserve University
Cleveland, OH

Accreditation Statement

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.25 Contact Hour.

Disclosures of Conflicts of Interest

Nancy L. Kuntz, MD

  • Grant Research Support: AveXis, Audentes Therapeutics, Biogen, Sarepta Therapeutics, Solid Biosciences.
  • Consultant: AveXis, Audentes Therapeutics, Biogen, Sarepta Therapeutics.

Thomas W. Prior, PhD, has no relevant financial relationships with commercial interest to disclose.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Instructions for Participation and Credit


  • You will need to log in to participate in the activity
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review video files/content until you finish the presentation.
  • At the end of the activity, “Educational Content/ Videos” will be available for your reference.
  • In order to receive a CME/CE Certificate, you must complete the activity.
  • Complete the Posttest and the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE Certificate upon completion of these steps.


Hardware and Software Requirements

This site is best viewed with an HTML5 compatible browser. You can visit the independent (3rd party) site to determine if you have the latest version of your browser.

Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player.

Disclosure of Unlabeled Use

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or the company that provided commercial support.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.